Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORTREL 1/35-28 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone inhibits gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additionally, increases cervical mucus viscosity and alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days, followed by a 7-day placebo period (if using 28-day pack) or continuous if using 21-day pack with 7-day off. Start on first day of menstrual period.
400 mg orally once daily with food.
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 13-27 hours (terminal). Context: steady-state after 5-7 days; dose adjustment in hepatic impairment.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Primarily hepatic via CYP3A4; ethinyl estradiol undergoes first-pass metabolism; norethindrone is metabolized via reduction and conjugation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal 60-70% (as glucuronide and sulfate conjugates), fecal 20-30% (via biliary excretion).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Norethindrone: 99% bound (SHBG, albumin); ethinyl estradiol: 98% bound (albumin, SHBG).
98% bound to albumin
Norethindrone: 4-5 L/kg (extensive tissue distribution); ethinyl estradiol: 2-4 L/kg (significant tissue uptake).
0.2-0.3 L/kg; indicates limited extravascular distribution
Norethindrone: 47-73% (oral); ethinyl estradiol: 38-48% (oral, first-pass metabolism).
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment (GFR >=30 m L/min). Not recommended for use in severe renal impairment (GFR <30 m L/min) due to potential for hormonal disturbances and adverse effects.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in acute liver disease, active hepatitis, or severe cirrhosis (Child-Pugh class C). For mild (Child-Pugh A) or moderate (Child-Pugh B) impairment, use is not recommended due to potential for altered metabolism; alternative contraception advised.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use in postmenarchal pediatric patients; safety and efficacy established for contraception in females of reproductive age. For adolescents, standard adult dosing may be used after menarche; individualize based on clinical judgment.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women; estrogen-containing contraceptives are not appropriate for this age group. No specific geriatric dosage adjustments applicable as therapy is not recommended.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular side effects from oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders,Cigarette smoking increases cardiovascular risk,Elevated blood pressure,Hepatic neoplasia,Gallbladder disease,Glucose intolerance,Ocular lesions (e.g., retinal thrombosis),Headache/migraine,Menstrual irregularities and breakthrough bleeding
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years (relative contraindication)
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels and risk of adverse effects. Avoid grapefruit products. No other significant food interactions; however, maintain consistent dietary habits as high-fat meals may delay absorption but not reduce overall bioavailability.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy category X. Significant risk of fetal harm in the first trimester (limb defects, cardiac anomalies) and second/third trimesters (genital abnormalities, neurodevelopmental effects). Use contraindicated in pregnancy.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted in breast milk. M/P ratio approximately 0.4. May reduce milk production and affect infant hormonal balance. Use with caution, monitor infant for jaundice and growth.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dosing adjustments required as drug is contraindicated in pregnancy. No pharmacokinetic data available for dose modification.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
NORTREL 1/35-28 contains norethindrone 1 mg and ethinyl estradiol 35 mcg. For COCs, consider that CYP3A4 inducers (e.g., rifampin, St. John's wort) may reduce contraceptive efficacy. If a patient misses two or more pills, use backup contraception for 7 days. The 28-day pack includes 21 active pills and 7 placebo pills to maintain the regimen.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time for 28 days; start the next pack immediately after finishing the current pack.,Do not skip pills; if you miss one, take it as soon as remembered. If you miss two or more, use backup contraception for 7 days.,This drug does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, headache, breast tenderness, and spotting. Contact your provider if you have severe abdominal pain, chest pain, or leg pain.,Do not smoke; smoking increases the risk of serious cardiovascular side effects, especially in women over 35.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORTREL 1/35-28 vs ADQUEY, answered by our medical review team.
NORTREL 1/35-28 is a Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone inhibits gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additionally, increases cervical mucus viscosity and alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORTREL 1/35-28 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORTREL 1/35-28 is: One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days, followed by a 7-day placebo period (if using 28-day pack) or continuous if using 21-day pack with 7-day off. Start on first day of menstrual period.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORTREL 1/35-28 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORTREL 1/35-28 is classified as Category C. Pregnancy category X. Significant risk of fetal harm in the first trimester (limb defects, cardiac anomalies) and second/third trimesters (genital abnormalities, neurodevelopmental. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.